Table 2 Baseline characteristics of studies included in this meta-analysis
Author | Year | Design | Treatment (LLIF) | Sample size | Age (years) | Sex (Male/Female) | Follow-up (months) |
|---|---|---|---|---|---|---|---|
Cheng | 2021 | Retrospective | Instrumented Stand-alone | 15 48 | 67.0 ± 10.0 | NA | 23.2 ± 11.5 |
Wu | 2021 | Retrospective | Instrumented Stand-alone | 25 36 | 65.1 ± 9.5 | 30/31 | 12 |
Li | 2021 | Prospective | Instrumented Stand-alone | 41 54 | 57.9 ± 8.2/60.3 ± 6.2 | 20/21 19/35 | 17.1 ± 3.5 16.3 ± 4.0 |
Jones | 2021 | Retrospective | Instrumented Stand-alone | 239 108 | 61.7 ± 11.1 | 174/173 | 12 |
Cai | 2021 | Retrospective | Instrumented Stand-alone | 25 41 | 62.16 ± 8.65/59.46 ± 8.46 | 12/13 22/19 | ≥ 6 |
He | 2020 | Retrospective | Instrumented Stand-alone | 41 32 | 61.0 ± 9.3/59.8 ± 13.7 | 11/30 10/22 | 24 |
Chen | 2019 | Retrospective | Instrumented Stand-alone | 26 27 | 61.5 ± 10.9/60.2 ± 11.3 | 7/19 15/12 | 24 |
Parker | 2017 | Retrospective | Instrumented Stand-alone | 78 54 | 31–86 | 45/87 | 24 |
Malham | 2017 | Prospective | Instrumented Stand-alone | 19 21 | 61.8 ± 10.3/65.2 ± 12.1 | 5/14 7/14 | 12 |
Aichmair | 2017 | Retrospective | Instrumented Stand-alone | 21 31 | 60.9 ± 10.6/62.5 ± 12.1 | 35/17 | 16.1 ± 9.8 |
Malham | 2012 | Prospective | Instrumented Stand-alone | 14 16 | 62.7 ± 10.5 | 10/20 | 12 |
Kim | 2012 | Retrospective | Instrumented Stand-alone | 4 4 | 64.0 ± 9.6/67.5 ± 8.3 | 1/3 1/3 | 2–8 |
Sharma | 2011 | Retrospective | Instrumented Stand-alone | 33 10 | 63.9 ± 10.2 | 16/27 | 12 |